IXJ ETF Analysis

Cette page a été traduite automatiquement de l'original anglais par IA ; la version anglaise fait foi. Lire la version anglaise

À titre informatif uniquement. Ne constitue pas un conseil financier.

Réponse Rapide

IXJ ETF has a last stored price of $100.86, as of the Oct 2, 2026 trading session. Holdings and weights below are as of Mar 15, 2026.

In the stored portfolio snapshot, the largest listed holding is Eli Lilly and Co (LLY) at 10.08%.

IXJ ETF — Price, Holdings & Analysis

Vue d'ensemble de l'ETF

The IXJ ETF aims to track the performance of an index composed of leading global healthcare companies. Unlike broad market ETFs, IXJ offers a focused approach, investing in a select group of established pharmaceutical, biotechnology, and healthcare services companies. The fund's concentrated portfolio, reflects a high-conviction strategy within the healthcare sector. Top holdings include pharmaceutical giants like Eli Lilly and Co (10.08%), Johnson & Johnson (7.22%), and AbbVie Inc (4.95%). This concentration means that the performance of these key companies will significantly impact IXJ's overall returns. The fund may be suitable for investors who have a bullish outlook on the healthcare sector and are seeking targeted exposure to its largest and most influential players. However, investors should be aware of the risks associated with such a concentrated portfolio. Past performance does not guarantee future results.

Mesures de Risque

IXJ's presents a significant concentration risk. The performance of a few key companies, such as Eli Lilly and Co (10.08%) and Johnson & Johnson (7.22%), will heavily influence the fund's overall returns. This lack of diversification can lead to greater volatility compared to broader healthcare ETFs or the overall market. The fund's sector focus also exposes it to risks specific to the healthcare industry, such as regulatory changes, patent expirations, and drug pricing pressures. While IXJ's beta of 0.66 suggests lower volatility than the broader market, this does not eliminate the risks associated with its concentrated and sector-specific nature. Investors should carefully consider their risk tolerance and investment objectives before investing in IXJ. Past performance does not guarantee future results.

Bêta: 0.66

Que détient IXJ ?

Participation	Pondération
Eli Lilly and Co (LLY)	10.08%
Johnson & Johnson (JNJ)	7.22%
AbbVie Inc (ABBV)	4.95%
Roche Holding AG (ROG.SW)	4.05%
AstraZeneca PLC (AZN.L)	3.91%
Novartis AG Registered Shares (NOVN.SW)	3.89%
Merck & Co Inc (MRK)	3.71%
UnitedHealth Group Inc (UNH)	3.21%
Amgen Inc (AMGN)	2.52%
Abbott Laboratories (ABT)	2.44%

Positions et pondérations au 15 mars 2026. Ces données du fonds datent de plus de 45 jours ; vérifiez les positions actuelles auprès de l’émetteur.

Rendement du Dividende

1.03%

Questions & Réponses

What is IXJ and what does it track?

IXJ is an ETF that provides investors with targeted exposure to leading global healthcare companies. It tracks an index composed of a select group of established pharmaceutical, biotechnology, and healthcare services companies.

This focused approach differentiates IXJ from broader healthcare ETFs that may include a wider range of companies and sub-sectors. As of 2026-03-15, IXJ offers a dividend yield of 1.03%.

What are the top holdings in IXJ?

IXJ's top holdings reflect its focus on established pharmaceutical and healthcare companies. As of 2026-03-15, the top three holdings are Eli Lilly and Co (LLY) at 10.08%, Johnson & Johnson (JNJ) at 7.22%, and AbbVie Inc (ABBV) at 4.95%.

These companies represent a significant portion of the fund's assets, highlighting the concentrated nature of IXJ's portfolio. Other notable holdings include Roche Holding AG (4.05%) and AstraZeneca PLC (3.91%).

Is IXJ a good long-term investment?

Whether IXJ is a suitable long-term investment depends on an individual's investment goals, risk tolerance, and outlook on the healthcare sector. IXJ offers targeted exposure to leading global healthcare companies, but its introduces concentration risk.

The fund's beta of 0.66 suggests lower volatility compared to the broader market, but this does not eliminate the risks associated with its sector-specific focus.

How does IXJ compare to similar ETFs?

IXJ distinguishes itself through its highly, focusing on established global healthcare giants. Other healthcare ETFs may offer broader diversification across a larger number of companies or focus on specific sub-sectors like biotechnology or medical devices.

When comparing IXJ to similar ETFs, factors such as expense ratios, AUM (assets under management), and investment strategy may be worth researching.

Does IXJ pay dividends?

Yes, IXJ distributes dividends to its shareholders. As of 2026-03-15, IXJ has a dividend yield of 1.03%. This yield represents the annual dividend payment as a percentage of the fund's share price.

Dividends can provide a source of income for investors and contribute to overall returns. However, dividend yields can fluctuate over time depending on the performance of the underlying holdings and the fund's distribution policy.

Avertissement : Ce contenu est fourni à titre informatif uniquement et ne constitue pas un conseil en investissement. Effectuez toujours vos propres recherches et consultez un conseiller financier.

Données fournies à titre informatif uniquement.

Rédigé par une machine, sans relecture page par page. Le contrôle éditorial est systémique : les règles et les sources sont vérifiées, pas chaque page.